NNVC NANOVIRICIDES, INC.
Pharmaceutical Preparations · NYSE · SEC CIK 1379006 · Fiscal year ends 06/30
Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-49.9%
TTM EPS YoY-8.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-179.2%
ROA-135.9%
ROIC (approx.)-196.2%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets33.5%
Debt / equity0.00x
Current ratio0.95x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.80x
Accruals ratio-27.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2027Q12026-09-30 | 2026Q4*2026-06-30 | 2026Q3*2026-03-31 | 2026Q2*2025-12-31 | 2026Q12025-09-30 | 2025Q4*2025-06-30 | 2025Q3*2025-03-31 | 2025Q2*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| R&D expense | $4.70M | $1.31M | $1.29M | $1.12M | $993,066 | $1.18M | $1.28M | $1.16M |
| SG&A expense | $1.07M | $936,316 | $744,276 | $1.11M | $803,619 | $938,195 | $966,905 | $902,700 |
| Operating income | -$5.77M | -$2.25M | -$2.03M | -$2.23M | -$1.80M | -$2.12M | -$2.25M | -$2.06M |
| Interest expense | — | — | — | — | — | $0 | $0 | $149 |
| Net income | -$5.74M | -$2.22M | -$1.99M | -$2.22M | -$1.79M | -$2.10M | -$2.22M | -$2.03M |
| EBITDA | -$5.64M | -$2.12M | -$1.90M | -$2.10M | -$1.67M | -$1.96M | -$2.06M | -$1.87M |
| EPS (basic) | -0.23 | — | -0.09 | -0.11 | -0.10 | — | -0.14 | -0.14 |
| EPS (diluted) | -0.23 | — | -0.09 | -0.11 | -0.10 | — | -0.14 | -0.14 |
| Weighted avg. shares (diluted) | 24.79M | — | 21.61M | 19.85M | 17.08M | — | 16.03M | 14.57M |
| Balance sheet | ||||||||
| Cash & equivalents | $2.58M | $2.79M | $3.21M | $5.15M | $1.13M | $1.56M | $2.54M | $3.96M |
| Current assets | $2.98M | $3.16M | $3.38M | $5.30M | $1.25M | $1.67M | $2.73M | $4.07M |
| PP&E, net | $6.28M | $6.40M | $6.53M | $6.66M | $6.79M | $6.83M | $6.98M | $7.17M |
| Intangibles | $306,701 | $308,769 | $310,836 | $312,904 | $314,971 | $317,039 | $319,106 | $321,174 |
| Total assets | $9.56M | $9.87M | $10.22M | $12.27M | $8.36M | $8.82M | $10.03M | $11.57M |
| Current liabilities | $3.15M | $1.19M | $1.07M | $1.20M | $1.18M | $1.31M | $1.20M | $1.18M |
| Total liabilities | $3.20M | $1.20M | $1.10M | $1.20M | $1.20M | $1.30M | $1.20M | $1.20M |
| Shareholders' equity | $6.41M | $8.68M | $9.15M | $11.07M | $7.17M | $7.52M | $8.83M | $10.39M |
| Shares outstanding | 25.55M | 23.01M | 21.65M | 21.60M | 17.56M | 16.61M | 16.07M | 15.64M |
| Cash flow statement | ||||||||
| Operating cash flow | -$3.64M | -$2.12M | -$1.93M | -$2.05M | -$1.59M | -$1.70M | -$1.99M | -$2.19M |
| Capital expenditure | — | $1 | $0 | -$1 | $84,317 | $10,200 | $0 | $0 |
| Free cash flow | — | -$2.12M | -$1.93M | -$2.05M | -$1.68M | -$1.71M | -$1.99M | -$2.19M |
| Investing cash flow | — | -$1 | $0 | $1 | -$84,317 | -$10,200 | $0 | $0 |
| Financing cash flow | $3.42M | $1.70M | -$6,742 | $6.07M | $1.25M | $728,080 | $575,503 | $2.28M |
| Depreciation & amortization | $126,123 | $127,682 | $127,566 | $131,016 | $130,752 | $159,059 | $189,114 | $193,816 |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.